Home Headline News Roche Holding Target Price $50

Roche Holding Target Price $50


Roche Holding said that the European Commission has approved its influenza treatment Xofluza.

The company said Xoflusa was also approved as a post-exposure prophylaxis, meaning as a preventative treatment for individuals who have come in contact with someone infected with an influenza virus.

The Commission’s approval–which comes in the wake of a November positive opinion from the Committee for Medicinal Products for Human Use–is based on the results of phase 3 Capstone-1, Capstone-2 and Blockstone studies, Roche said.

Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the bullish or bearish trend reflected in the lower ribbon.


Roche Holding is currently 1.3% above its 200-period moving average and is in an upward trend.

Our volume indicators reflect volume flowing into and out of Roche Holding at a relatively equal pace (neutral).

Our trend forecasting oscillators are currently bullish on Roche Holding and have had this outlook for the last 9 periods.

Overall, the bias in prices is: Upwards.

During the past 10 bars, there have been 6 white candles and 2 black candles for a net of 4 white candles.

During the past 50 bars, there have been 25 white candles and 23 black candles for a net of 2 white candles.

Previous articleTeladoc Health Breakout Possible
Next articleWall Street’s Key Stock Analysts Research Report, All Buys
HEFFX has become one of Asia’s leading financial services companies with interests in Publishing, Private Equity, Capital Markets, Mining, Retail, Transport and Agriculture that span every continent of the world. Our clearing partners have unprecedented experience in Equities, Options, Forex and Commodities brokering, banking, physical metals dealing, floor brokering and trading.